CD274 and breast carcinoma: The first FDA accelerated approval of an ICI for the treatment of breast cancer came in March 2019 when the anti-PD-L1 antibody atezolizumab was approved in combination with nab-paclitaxel as a first-line treatment for patients with PD-L1-positive, metastatic TNBC based on the IMpassion130 trial19.